Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
about
Predictors of beta-blocker intolerance and mortality in patients after acute coronary syndromeFibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionStatins for acute coronary syndromeHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisCombined therapy with statins and fibrates for people with dyslipidaemiaStatins for acute coronary syndromeInterventions to improve adherence to lipid lowering medicationHMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysisCombined therapy with statins and fibrates for people with dyslipidaemiaInterventions to improve adherence to lipid lowering medicationRisk factor thresholds: their existence under scrutinyCost effectiveness analysis of different approaches of screening for familial hypercholesterolaemiaEffect of rosuvastatin on outcomes in chronic haemodialysis patients - design and rationale of the AURORA study.Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapyStatin adverse effects : a review of the literature and evidence for a mitochondrial mechanismOpening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular riskRegional variation in out-of-hospital cardiac arrest incidence and outcomePleiotropic effects of statinsImplantable cardioverter defibrillators work--so why aren't we using them?Are statins anti-inflammatory?Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunitiesA review of clinical trials in dietary interventions to decrease the incidence of coronary artery diseaseDebate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low"Debate: "How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: "Below 100 mg/dl"The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice.A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline CharacteristicsDebate: Should statin be used in patients with heart failure?The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemiaAnti-atherogenic effects of fibrates in type 2 diabetesA cluster randomized trial to assess the impact of opinion leader endorsed evidence summaries on improving quality of prescribing for patients with chronic cardiovascular disease: rationale and design [ISRCTN26365328]Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS studyEvidence-based prescribing of statins: a developing world perspective.Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studiesProgression of coronary artery calcification at the crossroads: sign of progression or stabilization of coronary atherosclerosis?Pleiotropic effects of statinsThe effect of statins on average survival in randomised trials, an analysis of end point postponementStatins: definitive translational researchHigh-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis
P2860
Q21132471-E2FFB017-58CA-4D34-BFEB-FD78C21EC98EQ21246041-16F7C9CB-032A-48AE-A0B3-6D32B9517B05Q24193862-8E673967-66C5-4A05-B522-8D510A019F07Q24194514-ACD7717A-A4CB-406C-B968-3F4B7E99372AQ24195172-B7F5ADB6-F97F-44DC-8F8D-F414E4CAB804Q24236697-0DD530D0-A00F-4068-934A-CA7D71D96EA3Q24236817-A6B52A7C-BD31-41DD-A3CA-A846C1969C0FQ24241472-DF402BCC-FAB3-4C9B-8A49-3B9FB9D2DB18Q24243737-618F92D8-F4E6-4C5D-AC92-D50A0F94FD5AQ24245739-CEFEFA16-AA7C-44B4-B6F1-AD16DF67238CQ24527206-7BA62CD1-5B57-4C3A-B9B4-962FA2C155E6Q24528552-F1B2062F-5AFE-48B5-BCD7-7D91958C091FQ24531203-45FFBA45-B2C2-49BA-A5DA-CBCCCC8C5E17Q24594496-EC5FB0B0-6C02-46BB-BBB6-4C840B5D320DQ24603957-5502E4E2-32B6-4625-B8F6-08A654C73A3EQ24626884-1DC3F157-8996-4877-8DD7-0FA28D7F12D0Q24635224-B1391F49-0815-4F80-B84C-6A9D6912FCB6Q24647863-8AC32578-D198-41B4-BD88-4039603FC9DFQ24685141-50142DE6-E6EB-40CF-AAE7-1D0C3A37A354Q24792912-BCCF50ED-D7EA-499C-B6DA-DE74285B33BBQ24793111-9E59CACD-E033-4CC4-BE0B-CD9B276F7F2BQ24793178-EE1B02E3-05F7-4F35-B989-75B3F695D51CQ24793416-1D087045-7782-4BBB-BAEA-CB8F0D7BCE1CQ24793512-521C9179-BCF0-4700-9708-51DBBE6D2EF9Q24793837-539A135B-DBBE-4173-B042-D33B17FAE7DAQ24794251-BA6E95A6-185E-4A36-BF69-CABBCC26898DQ24794358-6C97C243-74CA-4841-AF24-E716D4F6163AQ24799305-FE1828B1-5325-4824-8AD1-DDA506CCED67Q24804541-CD7F9CCD-DF17-4620-8BA2-96741210C2DAQ24805607-4E90B1F8-7D16-4912-BA51-9BA9651D5E05Q24806921-73515FE6-7FED-4E9C-9252-A1BD6BE3F9A7Q24811254-E9CD279C-2110-4136-98F4-433E6B3E8AF4Q24814804-4B6C9980-535C-4ECD-8D5D-7711E55E6A80Q25255887-1EE23060-8A04-4BFB-A2D6-E2D03A497343Q26746907-6427C30A-E20C-44CA-AEB2-5286F04E55E6Q26747351-F570A987-BD70-45F9-8F20-33A6F573425FQ26783220-72EC2185-6025-4381-A6C2-7782D89273D7Q26786733-CAE8BE3B-B0BE-4544-B75C-1E8D37A95C9DQ26851528-FD686258-03F0-44F4-872C-E8A5B2D925F2Q26853061-894EFA67-36F9-46D8-A456-CF354FEE10B0
P2860
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Prevention of cardiovascular e ...... of initial cholesterol levels
@ast
Prevention of cardiovascular e ...... of initial cholesterol levels
@en
type
label
Prevention of cardiovascular e ...... of initial cholesterol levels
@ast
Prevention of cardiovascular e ...... of initial cholesterol levels
@en
prefLabel
Prevention of cardiovascular e ...... of initial cholesterol levels
@ast
Prevention of cardiovascular e ...... of initial cholesterol levels
@en
P3181
P1476
Prevention of cardiovascular e ...... of initial cholesterol levels
@en
P304
P3181
P356
10.1056/NEJM199811053391902
P407
P577
1998-11-05T00:00:00Z